Nu nu

Manufactured by Charles River Laboratories

Sourced in United States, China

Nu/Nu is a mouse model developed by Charles River Laboratories. It is a strain of athymic nude mice that lack a functional thymus gland, resulting in a deficiency of T cells. This model is commonly used in research applications that require an immunocompromised animal.

Automatically generated - may contain errors

Lab products found in correlation

Matrigel, by BD (7 mentions) Fetal bovine serum (fbs), by Thermo Fisher Scientific (5 mentions) Matrigel basement membrane matrix, by BD (2 mentions) Xenogen ivis spectrum, by PerkinElmer (2 mentions) C57bl 6, by Charles River Laboratories (2 mentions) C57bl 6 mice, by Jackson ImmunoResearch (2 mentions) Ne 121, by Innovative Research (1 mentions) Ivis spectrum imaging system, by PerkinElmer (1 mentions) Bt474, by American Type Culture Collection (1 mentions) Ivis 200 imaging system, by PerkinElmer (1 mentions) Ivis 200, by PerkinElmer (1 mentions) Charge coupled device camera, by PerkinElmer (1 mentions) Living image software, by PerkinElmer (1 mentions) Growth factor reduced matrigel, by BD (1 mentions) Multispectral fx, by Carestream (1 mentions) Matrigel matrix, by Corning (1 mentions) Lncap cells, by BD (1 mentions) Pbs matrigel, by BD (1 mentions) Fetal bovine serum (fbs), by Wisent (1 mentions) Lncap and pc3 human prostate cancer cells, by American Type Culture Collection (1 mentions)

74 protocols using nu nu

Nude Mouse Xenograft Tumorigenesis

Check if the same lab product or an alternative is used in the 5 most similar protocols

The nude mouse xenograft tumorigenesis study protocol was reviewed and approved by Michigan State University Institutional Animal Care and Use Committee. Six-week old female nude mice (Nu/Nu) were purchased from Charles River Laboratory. After one week acclimation, mice were randomly divided into 4 groups and 5 mice in each group. Passage-matched control cells, arsenic exposure alone-transformed cells, BaP exposure alone-transformed cells, or arsenic plus BaP co-exposure-transformed cells (0.25 × 10⁶ cells in 0.1 ml of 1:1 growth factor-reduced matrigel and PBS) were injected subcutaneously into the right flank of female nude mice (Nu/Nu, Charles River laboratories, five mice in each group). After cell injection, nude mice were maintained under specific pathogen-free conditions. All animals were euthanized 12 weeks after cell injection, and the xenograft tissues were harvested and fixed with 10% formalin solution.

Wang Z., Yang P., Xie J., Lin H.P., Kumagai K., Harkema J, & Yang C. (2020). Arsenic and benzo[a]pyrene co-exposure acts synergistically in inducing cancer stem cell-like property and tumorigenesis by epigenetically down-regulating SOCS3 expression. Environment international, 137, 105560.

+ Open protocol

+ Expand

Xenograft Tumor Formation Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols

H1299 Tet-on p53^3KR ctrl crispr and ALOX12 crispr cells were pretreated with or without doxycycline (0.5ug/mL) for 48 h, then the cells were trypsinized and counted. 1.0× 10⁶ cells were mixed with Matrigel (BD Biosciences) at 1:1 ratio (v/v) and injected subcutaneously into nude mice (NU/NU; Charles River). Mice were fed with either control food or food containing doxycycline hyclate (Harlan, 625mg/kg). After four weeks, the mice were killed and the tumors were weighed and recorded. The study is compliant with all relevant ethical regulations for animal experiments. All the experimental protocols were approved by the Institutional Animal Care and Use Committee of Columbia University.

Chu B., Kon N., Chen D., Li T., Liu T., Jiang L., Song S., Tavana O, & Gu W. (2019). ALOX12 is required for p53-mediated tumor suppression through a distinct ferroptosis pathway. Nature cell biology, 21(5), 579-591.

+ Open protocol

+ Expand

Hydrogel Implantation and In Vivo Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

Hydrogel constructs were implanted as previously described [ 32 ]. Briefly, 10-week old male athymic nude mice (NU/NU; Charles River, Wilmington, MA) were anesthetized and prepped. Four medial vertical incisions, 2 on each side, were made on the dorsum of each mouse, followed by minimal dissection of the subcutaneous tissue to create pockets just large enough to accommodate 1 disc. Four discs from a single passage (P3, P4, or P5) were implanted into each mouse, with one disc per subcutaneous pocket. Incisions were closed with interrupted nylon sutures, and an overlying sterile, occlusive dressing was placed prior to reversal from anesthesia.
At 1 and 3 months, animals were sacrificed using carbon dioxide asphyxiation with cervical dislocation. Discs were harvested, weighed, measured in height and diameter, and imaged. One disc per mouse was fixed in 10% neutral buffered formalin for 48 hours and then transferred to 70% ethanol for histologic analyses. The remaining discs were flash frozen in liquid nitrogen for biochemical and biomechanical analyses. A total of 94 discs were explanted for analysis, 32 from P3, 32 from P4, and 30 from P5.

Bernstein J.L., Cohen B.P., Lin A., Harper A., Bonassar L.J, & Spector J.A. (2018). Tissue Engineering Auricular Cartilage Using Late Passage Human Auricular Chondrocytes. Annals of plastic surgery, 80(4 Suppl 4), S168-S173.

+ Open protocol

+ Expand

Establishing Leiomyosarcoma Patient-Derived Xenografts

Check if the same lab product or an alternative is used in the 5 most similar protocols

Tumor samples isolated for xenografting experiments were obtained from patients undergoing clinically indicated surgery and following written informed consent to a Dana-Farber Cancer Institute (DFCI) and Brigham and Women’s Hospital (BWH) IRB-approved and U.S. Common Rule compliant research protocol. Fresh or cryopreserved tumors were implanted subcutaneously into ~6 week old female nude mice (NU/NU; Charles River Laboratories). Histologic review by a pathologist with expertise in sarcoma was performed to confirm the diagnosis of leiomyosarcoma, assess mitotic rate and grade, and compare parental tumors to PDX. Three attempted xenografts had no archival parental tumor available for pathology review, and mitotic rate and grade were obtained from the original clinical report. LMS7 and LMS29 were grown in the presence of subcutaneously implanted 17β-estradiol-sustained release pellets (Innovative Research of America, Cat# NE-121).

Hemming M.L., Bhola P., Loycano M.A., Anderson J.A., Taddei M.L., Doyle L.A., Lavrova E., Andersen J.L., Klega K.S., Benson M.R., Crompton B.D., Raut C.P., George S., Letai A., Demetri G.D, & Sicinska E. (2022). Preclinical modeling of leiomyosarcoma identifies susceptibility to transcriptional CDK inhibitors through antagonism of E2F-driven oncogenic gene expression. Clinical cancer research : an official journal of the American Association for Cancer Research, 28(11), 2397-2408.

+ Open protocol

+ Expand

Establishment and Imaging of Tumor Models

Check if the same lab product or an alternative is used in the 5 most similar protocols

Four-to-six-week-old female nude mice (Nu-Nu) were purchased from Charles River Laboratories (Wilmington, MA). The studies were conducted with the approval of and in accordance with guidelines of the Institutional Animal Care and Use Committee at the University of Oklahoma Health Sciences Center, Oklahoma City, OK. For establishing subcutaneous (s.c.) tumors, mice were anesthetized with 2% isoflurane and injected with A549 and HCC827 tumor cells (5×10⁶ cells in 100 µl of PBS) subcutaneously in the lower right flank of mice. For studies involving bioluminescence imaging, A549 stably expressing luciferase (luc; A549-luc) was used. When the tumors reached a size of about 50–100 mm³ the mice were randomized and used for biodistribution and efficacy studies as described below.
For establishing experimental lung metastasis, A549-luc cells (5×10⁶ cells in 100 µl of PBS) were injected intravenously (i.v.) via tail-vein. Tumor formation in the lungs was detected by intraperitoneally (i.p.) injecting D-luciferin (D-Luc; 150 mg/kg) and measuring bioluminescence using the IVIS^® Spectrum Imaging System (Perkin Elmer). When the tumor bioluminescence signals reached approximately average radiance of 5000 p/s/cm²/sr, mice were randomly assigned to treatment groups and efficacy studies conducted.

Muralidharan R., Babu A., Amreddy N., Srivastava A., Chen A., Zhao Y.D., Kompella U.B., Munshi A, & Ramesh R. (2017). Tumor-targeted nanoparticle delivery of HuR siRNA inhibits lung tumor growth in vitro and in vivo by disrupting the oncogenic activity of the RNA-binding protein HuR. Molecular cancer therapeutics, 16(8), 1470-1486.

+ Open protocol

+ Expand

Metastatic Breast Cancer Mouse Model

Check if the same lab product or an alternative is used in the 5 most similar protocols

All animal procedures were performed in accordance with federal guidelines for the care and use of laboratory animals, and were approved by the Institutional Animal Care and Use Committee (IACUC) at the Georgia Institute of Technology. Five-week old female nude mice (Nu/Nu, Charles River) were inoculated in the right caudal mammary fat pad with 2×10⁶ human breast adenocarcinoma cells in 50% Matrigel (MDA-MB231-Red-FLuc-GFP, PerkinElmer) for the metastatic group. The MDA-MB231-Red-FLuc-GFP are transfected with green fluorescence protein (GFP) to be detected in histology. For the non-metastatic control group, mice were inoculated similarly with non-metastatic human ductal carcinoma cells (BT474, ATCC). Tumors were allowed to grow up to a 10 mm diameter prior to imaging studies. Naïve mice of the same strain and age were used as an additional control group.

Dumani D.S., Sun I.C, & Emelianov S.Y. (2019). Ultrasound-guided Immunofunctional Photoacoustic Imaging for Diagnosis of Lymph Node Metastases. Nanoscale, 11(24), 11649-11659.

+ Open protocol

+ Expand

Apratoxin S8 Efficacy in Nude Mouse Xenograft

Check if the same lab product or an alternative is used in the 5 most similar protocols

Example 17

3-5 week old female nude mice (nu/nu) were obtained from Charles River Laboratory (Wilmington, Mass.). 1×10⁶HCT116 cells in a volume of 100 μL of sterile saline were injected subcutaneously on the left rear flank of a nude mouse to establish tumors. Tumor dimensions were measured using calipers every day and tumor volumes were calculated using the formula W²×L×0.5, where width (W)≤length (L). Tumors with a starting volume bigger than 100 mm³were excluded from the analysis. Mice were injected intraperitoneally with the doses of 2 μg/mouse (0.1 mg/kg), 5 μg/mouse (0.25 mg/kg) of apratoxin S8 (BM) or solvent (DMSO) control every day until the tumor size in one dimension reached 15 mm and tumor tissue was harvested on the following day. 50 mg of tumor tissue was sonicated in PhosphoSafe lysis buffer (EMD chemicals, Inc) and used for immunoblot analysis described as the above. All studies were carried out under the protocol approved by the Institutional Animal Care and Use Committee at the University of Florida.

US11718645B2. Macrocyclic therapeutic agents, methods of manufacture, and methods of treatment (2023-08-08). University of Florida Research Foundation, Incorporated [US]. Inventors: Hendrik Luesch [US], Qi-Yin Chen [US].

+ Open protocol

+ Expand

HCT116 Tumor Growth Inhibition

Check if the same lab product or an alternative is used in the 5 most similar protocols

Three–five week old
female nude mice (nu/nu) were obtained
from Charles River Laboratory (Wilmington, MA). One ×10⁶ HCT116 cells in a volume of 100 μL of sterile saline were
injected subcutaneously on the left rear flank of a nude mouse to
establish tumors. Tumor dimensions were measured using calipers every
day, and tumor volumes were calculated using the formula W² × L × 0.5, where width (W) ≤ length (L). Tumors with a starting
volume bigger than 100 mm³ were excluded from the analysis.
Mice were injected intraperitoneally with the doses of 2 μg/mouse
(0.1 mg/kg), 5 μg/mouse (0.25 mg/kg) of 1c or solvent
(DMSO) control every day (25 μL) until the tumor size in one
dimension reached 15 mm and tumor tissue was harvested on the following
day. Finally, 50 mg of tumor tissue was sonicated in PhosphoSafe lysis
buffer (EMD chemicals, Inc.) and used for immunoblot analysis described
as the above. All studies were carried out under the protocol approved
by the Institutional Animal Care and Use Committee at the University
of Florida.

Chen Q.Y., Liu Y., Cai W, & Luesch H. (2014). Improved Total Synthesis and Biological Evaluation of Potent Apratoxin S4 Based Anticancer Agents with Differential Stability and Further Enhanced Activity. Journal of Medicinal Chemistry, 57(7), 3011-3029.

+ Open protocol

+ Expand

In Vivo Chondrosarcoma Tumor Growth Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols

To evaluate the in vivo effects of TOMM20 overexpression on chondrosarcoma tumor growth, cells were injected into the flank of athymic NCr nude mice (Nu/Nu; Charles River at 6 weeks of age). All animals were maintained in a pathogen-free environment/barrier facility at the Sidney Kimmel Cancer Center at Thomas Jefferson University. The Institutional Animal Care and Use Committee (IACUC) approved all animal protocols and all experiments were performed in accordance with the National Institute of Health guidelines. U2975 cells were injected into the flank of male nude mice and CH2879 cells were injected into the flank of female nude mice following isoflurane anesthesia. For these studies, 2 million cancer cells were resuspended in 100μL of sterile PBS before injection. For each mouse experiment there were 5 mice injected bilaterally per experimental group for a total of 10 per group. Mice were sacrificed 4-12 weeks post-injection via CO2 inhalation and tumors were excised. Tumor volume was calculated using the formula V=X^2*Y/2 where V is the tumor volume, X is the length of the short axis and the Y is the length of the long axis measured using electronic calipers and tumor weight was measured in grams. Statistical analysis was performed using the Mann Whitney U Test in GraphPad Prism. Values of p<0.05 were considered statistically significant.

Roche M.E., Lin Z., Whitaker-Menezes D., Zhan T., Szuhai K., Bovee J.V., Abraham J.A., Jiang W., Martinez-Outschoorn U, & Basu-Mallick A. (2020). Translocase of the outer mitochondrial membrane complex subunit 20 (TOMM20) facilitates cancer aggressiveness and therapeutic resistance in chondrosarcoma. Biochimica et biophysica acta. Molecular basis of disease, 1866(12), 165962.

+ Open protocol

+ Expand

Efficacy of Compound (3) on SKOV-3 Xenografts

Check if the same lab product or an alternative is used in the 5 most similar protocols

Example 5

The effects of exemplary compounds of the invention on the growth of SKOV-3 tumor xenographs in nude mice were investigated. Substantively, four- to six week-old immunodeficient nude mice (NU/NU; strain code 088/homozygous) (Charles River Laboratories, Wilmington, Mass.) were maintained at a temperature of 22±1° C. and a relative humidity of 55±5%, with a 12 h light/dark cycle. SKOV-3 cells were cultured to 80% confluence, washed in PBS twice, harvested by hypsination, pooled in complete medium, washed in PBS twice, and 2×10⁶cells/inoculate were suspended in 0.1 ml of matrigel and inoculated subcutaneously in the flank of mice. Mice with developing tumors after two weeks were randomly assigned to experimental groups. Compound (3) was prepared as a stock solution of 1 mM in 100% EtOH and diluted 1:40 in PBS for administration. Mice were treated intraperiotoncally every other day with either vehicle control (control group; 7 animals) or 300 μl (10 mg/kg bwt) of MT19c (n=7) for 40 days. Mice were weighed and tumor size caculated using a caliper every 5 days.

FIG. 7 illustrates the finding that Compound (3) reduces the tumor burden in one such xenograph model.

US11034719B2. 7-dehydrocholesterol derivatives and methods using same (2021-06-15). University of Rochester [US]. Inventors: Rakesh K. Singh [US], Richard G. Moore [US].

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!